Two clinical cases have documented acute periorbital inflammation following the intended subconjunctival administration of mitomycin C during glaucoma filtering procedures. Mitomycin C is widely employed as an adjunctive antifibrotic agent in glaucoma filtration surgery and bleb revision. While ocular toxicity from the drug is well recognized, acute inflammatory responses involving the surrounding periorbital tissues remain rarely described in ophthalmic literature.
The first documented case involved a 36-year-old Thai woman diagnosed with juvenile open-angle glaucoma who underwent a trabeculectomy augmented with a subconjunctival mitomycin C injection at a dose of 20 micrograms in 0.1 milliliters. On the first postoperative day, the patient developed marked painful right upper eyelid edema, complete ptosis, chemosis, and pronounced limitation of extraocular movements.
Because an infectious etiology could not initially be excluded upon clinical presentation, clinicians initiated antimicrobial therapy in conjunction with corticosteroids. Following this intervention, clinical improvement was evident by the following day, progressing to complete resolution of symptoms and ocular signs within two weeks of presentation.
The second case report detailed a 62-year-old Thai man with primary open-angle glaucoma who underwent bleb needling supplemented with subconjunctival mitomycin C at a dose of 10 micrograms in 0.1 milliliters. Within five hours following the intervention, the patient developed left upper eyelid swelling and binocular diplopia.
Clinical evaluation subsequently revealed incomplete ptosis alongside marked limitation of medial gaze in the affected eye. The patient received treatment consisting of topical antimicrobial therapy paired with corticosteroids, leading to complete recovery of ocular motility and full resolution of the localized periorbital inflammation within three weeks.
Researchers observed that the short latency following mitomycin C exposure, coupled with the absence of convincing progressive infectious features, suggests a sterile toxic-inflammatory reaction. The clinical manifestations may be potentially related to the posterior anatomical spread of the antimetabolite within the orbit.
The authors noted that definitive causality cannot be established solely from these two isolated clinical presentations, emphasizing that active infection must always be considered during initial evaluation. Maintaining clinical awareness of this potential adverse event facilitates prompt diagnostic evaluation and appropriate therapeutic management following mitomycin C-augmented glaucoma interventions.
Subject of Research: Acute periorbital inflammation associated with subconjunctival mitomycin C in glaucoma surgery
Article Title: Acute periorbital inflammation following subconjunctival mitomycin C in trabeculectomy and bleb needling: two case reports
Article References: Euswas, S., Srisombut, T., Khomate, W., Kangwanwongpaisan, C., Supakontanasan, W., Petpiroon, P., & Suwan, Y. (2026). Acute periorbital inflammation following subconjunctival mitomycin C in trabeculectomy and bleb needling: two case reports. BMC Ophthalmology. https://doi.org/10.1186/s12886-026-05550-w
Image Credits: AI Generated
DOI: 10.1186/s12886-026-05550-w
Keywords: glaucoma filtration surgery, mitomycin C, trabeculectomy, bleb needling, periorbital inflammation, ocular toxicity, antifibrotic agents, ptosis, chemosis, diplopia, extraocular motility, ophthalmology, case report, corticosteroid therapy, sterile inflammation
News Source: Ophelia Keating. (November 20, 2026). Rare Periorbital Inflammation Reported After Subconjunctival Mitomycin C in Glaucoma Procedures. Scienmag.



